Glaxo Recieves FDA Approval on Complete Vaccine Delivery System
PHILADELPHIA, Pa-A combined hepatitis A and B pediatric vaccine within a new safety needle system will soon be on the market. The Food and Drug Administration (FDA) has approved the GlaxoSmithKline Safety Tip-Lok prefilled Tip-Lok syringes, packaged with BD SafetyGlide needles for pediatric does of Havrix (hepatitis A vaccine, inactivated) and Engerix-B (hepatitis B vaccine, recombinant).
The system is the first pediatric vaccine available with the new safety needle system and the only vaccines available with the all-in-one delivery system. This meets the Occupational Safety and Health Administration's (OSHA) newly revised bloodborne pathogens standard.
The system works by using a BS SafetyGlide needle that shields the needle tip after activation, therefore helping prevent needlestick accidents. The Centers for Disease Control and Prevention (CDC) has estimated that safety devices may prevent 88% of needlestick injuries in the future.
For more information about the system or the vaccines, visit www.glaxosmithkline.com.
